Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, February 8, 2016

MS Neurologist Argues for Continued Use of Natalizumab as Disease Treatment

In a recent study of more than 1,200 patients with multiple sclerosis (MS), a research team reported that treatment with the drug natalizumab (Tysabri) could lead to a tenfold increase in the levels of blood antibodies associated with a virus causing a rare but severe brain disease known as progressive multifocal leukoencephalopathy (PML)MS Neurologist Argues for Continued Use of Natalizumab as Disease Treatment The study, “Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values,” was published in the journal Neurology: Neuroimmunology and Neuroinflammation and recently discussed in a Multiple Sclerosis News Today article.
The John Cunningham virus (JCV) is responsible for PML development, especially in individuals who have a weakened immune system or are undergoing immunosuppressive treatments. PML leads to the destruction of white matter in the brain.
However, increasing levels of JCV-antibodies do not necessary translate into a higher risk for patients to develop PML, as neurologists Adil Javed, MD, PhD, and Anthony Reder, MD, from the University of Chicago, said in a corresponding editorial.
Following the study publication, Dr. Javed highlighted the benefits of natalizumab as therapy for MS auch_029791-1nd explained its mechanism of action in a University of Chicago news release. “MS is an autoimmune disease, meaning that it’s a disease of mistaken self identity. The body’s own immune system attacks myelin, an essential layer of insulation around nerve fibers. Without this protective layer, neurons in the central nervous system misfire or fail to fire at all, causing muscle weakness, balance and coordination problems, i.e. disability” he said. “Natalizumab blocks migration of immune cells into the brain and thereby leads to an immunosuppressive state in the central nervous system. It’s by this mechanism that it prevents immune cells from destroying the body’s own myelin. Due to its potent effects on the immune system and the demonstrated high efficacy of the drug inclinical trials in comparison to the older agents, natalizumab was a game changer when it came out in 2004. MS neurologists all thought, ‘why shouldn’t every MS patient be on this drug?’”
When asked if the increase in JCV antibodies in MS patients meant that they were 10 times more likely to develop PML, Dr. Javed said: “Absolutely not. When we see rising antibody levels, or titer, we assume that there must be more replication of the virus. The higher the replication rate of the virus, the higher the chance that the virus could infect brain cells. But this is all based on assumptions and circumstantial evidence. There has never been a good study that shows that rising antibody titers are proportionally correlated with higher viral replication or load. The fact remains that even though JC virus-antibody levels rise over time while on natalizumab therapy, the risk of PML over time continues to remain relatively low.”

MS Views and News 
helps to provide educational information for persons affected by MS
Keep current with Multiple Sclerosis news and information 
by opting-in to our website: click here - thank you

No comments: